Classification of myasthenia gravis based on autoantibody status

Archives of Neurology

Volumn 64, Issue 8, 2007, Pages 1121-1124

  Suzuki, Shigeaki ^a   Utsugisawa, Kimiaki ^b   Nagane, Yuriko ^b   Satoh, Takashi ^a   Terayama, Yasuo ^c   Suzuki, Norihiro ^a   Kuwana, Masataka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hanamaki General Hospital   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; POTASSIUM CHANNEL KV1.1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; MYASTHENIA GRAVIS; MYOCARDITIS; MYOSITIS; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SEROLOGY; THYMOMA;

ADULT; AGE FACTORS; AGED; AUTOANTIBODIES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOPRECIPITATION; KV1.4 POTASSIUM CHANNEL; MALE; MIDDLE AGED; MUSCLE PROTEINS; MYASTHENIA GRAVIS; MYOCARDITIS; MYOSITIS; PROTEIN KINASES; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THYMOMA; THYMUS NEOPLASMS;

EID: 34547878654     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.8.1121     Document Type: Article

References (17)

1. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127(3):701-712.
2. + channels: subunit specificity correlates with clinical manifestations. Brain. 2006;129(6):1570-1584.
3. Suzuki S, Satoh T, Yasuoka H, et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol. 2005;170(1-2):141-149.
4. Agius MA, Richman DP, Vincent A. Specific antibodies in the diagnosis and management of autoimmune disorders of neuromuscular transmission and related diseases. In: Kaminski HJ, ed. Myasthenia Gravis and Related Disorders. Totowa, NJ: Humana Press; 2003:177-196.
5. Voltz RD, Albrich WC, Nagele A, et al. Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology. 1997;49(5):1454-1457.
6. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol. 2000;57(11):1596-1600.
7. Yamamoto AM, Gajdos P, Eymard B, et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol. 2001;58(6):885-890.
8. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology. 2001;57(9):1579-1582.
9. Somnier FE, Engel PJH. The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999. Neurology. 2002;59(1):92-98.
10. Chen XJ, Qiao J, Xiao BG, Lu CZ. The significance of titin antibodies in myasthenia gravis: correlation with thymoma and severity of myasthenia gravis. J Neurol. 2004;251(8):1006-1011.
11. Farrugia ME, Dobson MD, Clover L, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain. 2006;129(6):1481-1492.
12. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797- 1810.
13. Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55(1):16-23.
14. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc. 2000;48(11):1442-1448.
15. Aarli JA. Titin, thymoma, and myasthenia gravis. Arch Neurol. 2001;58(6):869-870.
16. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol. 2005;62(3):442-446.
17. Mygland A, Vincent A, Newsom-Davis J, et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol. 2000;57(4):527-531.